SperlingLSMechanickJINeelandIJ, et al.The CardioMetabolic Health Alliance: working toward a new care model for the metabolic syndrome. J Am Coll Cardiol2015; 66(9): 1050–1067.
2.
GurkaMJLillyCLOliverMN, et al.An examination of sex and racial/ethnic differences in the metabolic syndrome among adults: a confirmatory factor analysis and a resulting continuous severity score. Metabolism2014; 63(2): 218–225.
3.
DeBoerMDGurkaMJGoldenSH, et al.Independent associations between metabolic syndrome severity and future coronary heart disease by sex and race. J Am Coll Cardiol2017; 69(9): 1204–1205.
4.
Ladeiras-LopesRFontes-CarvalhoRVilelaEM, et al.Diastolic function is impaired in patients with prehypertension: data from the EPIPorto study. Rev Esp Cardiol (Engl Ed)2018; 71(11): 926–934.
5.
Cortez-DiasNMartinsSBeloA, et al.Comparison of definitions of metabolic syndrome in relation to risk for coronary artery disease and stroke. Rev Port Cardiol2011; 30(2): 139–169.
6.
NaguehSFAppletonCPGillebertTC, et al.Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr2009; 10(2): 165–193.
7.
NaguehSFSmisethOAAppletonCP, et al.Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging2016; 17(12): 1321–1360.
8.
MitterSSShahSJThomasJD. A test in context: E/A and E/e' to assess diastolic dysfunction and LV filling pressure. J Am Coll Cardiol2017; 69(11): 1451–1464.
9.
LourencoAPLeite-MoreiraAFBalligandJL, et al.An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur J Heart Fail2018; 20(2): 216–227.
10.
ZhangZYMarrachelliVGYangWY, et al.Diastolic left ventricular function in relation to circulating metabolic biomarkers in a population study. Eur J Prev Cardiol2019; 26(1): 22–32.
11.
AlmeidaJGFontes-CarvalhoRSampaioF, et al.Impact of the 2016 ASE/EACVI recommendations on the prevalence of diastolic dysfunction in the general population. Eur Heart J Cardiovasc Imaging2018; 19(4): 380–386.
12.
Ladeiras-LopesRAraujoMSampaioF, et al.The impact of diastolic dysfunction as a predictor of cardiovascular events: a systematic review and meta-analysis. Rev Port Cardiol. In press.
13.
GoharAKievitRFValstarGB, et al.Opportunistic screening models for high-risk men and women to detect diastolic dysfunction and heart failure with preserved ejection fraction in the community. Eur J Prev Cardiol2019; 26(6): 613–623.
14.
MohanMAl-TalabanySMcKinnieA, et al.A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. Eur Heart J2019; 40: 3409–3417.
15.
Ladeiras-LopesRFontes-CarvalhoRBettencourtN, et al.METformin in Diastolic Dysfunction of MEtabolic syndrome (MET-DIME) trial: rationale and study design: MET-DIME trial. Cardiovasc Drugs Ther2014; 28(2): 191–196.
